Ixico secures new contract with US-based client.

Neuroscience imaging firm Ixico has signed a contract with a new US-based client to provide imaging services for a Phase 2 Huntington's Disease clinical trial.

Ixico
10 December 2024 10:45:23

Source: Sharecast

Ixico said on Tuesday that the contract value, which will be delivered over approximately two and a half years, was worth more than £500,000 to the company.

The AIM-listed firm added that the contract award reinforced its "sustained positive commercial momentum" and aligns with its strategic pillars to drive expansion and growth.

Chief executie Bram Goorden said: "We are delighted to announce our involvement in this Phase 2 clinical trial, which aims to address the urgent need for effective treatments for Huntington's disease.

"This contract further demonstrates Ixico's expertise in supporting neurodegenerative disease trials, reinforcing our role as a trusted partner for sponsors."

As of 1045 GMT, Ixico shares were up 0.093% at 10.76p.

Reporting by Iain Gilbert at Sharecast.com

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.